Breaking News Instant updates and real-time market news.

JNP

Juniper Pharmaceuticals

$5.35

-0.1 (-1.83%)

, MKGAY

Merck KGaA

$38.36

(0.00%)

07:25
01/08/18
01/08
07:25
01/08/18
07:25

Juniper Pharmaceuticals announces extension of supply agreement for CRINONE

Juniper Pharmaceuticals (JNP) announced the extension of its supply agreement for CRINONE with an affiliate of Merck KGaA (MKGAY), Darmstadt, Germany. The amended agreement extends the supply term an additional 4.5 years and at least through to December 31, 2024. The current term was due to expire in May 2020. Merck KGaA, Darmstadt, Germany has marketing rights worldwide except the United States, where CRINONE is marketed by Allergan (AGN). Under the terms of the amended license and supply agreement, Juniper will remain the supplier of CRINONE to Merck KGaA, Darmstadt, Germany and will continue to sell CRINONE to Merck KGaA, Darmstadt, Germany for the more than 90 countries outside of the U.S. where CRINONE is sold. The agreement also sets from 1 July 2020, a volume tiered, fixed price per unit with minimum annual volume guarantees. In addition, Juniper has committed to increase the capacity of its supply chain in line with the projected growth of the product. Juniper previously reported that CRINONE product revenues increased 19% year-over-year in the third quarter of 2017. The Company recently announced that it expects continued strong double-digit revenue growth for its core business, CRINONE and JPS, in 2018.

JNP

Juniper Pharmaceuticals

$5.35

-0.1 (-1.83%)

MKGAY

Merck KGaA

$38.36

(0.00%)

AGN

Allergan

$172.29

0.71 (0.41%)

  • 08

    Jan

  • 16

    Feb

  • 25

    Mar

JNP Juniper Pharmaceuticals
$5.35

-0.1 (-1.83%)

01/02/18
ROTH
01/02/18
INITIATION
Target $12
ROTH
Buy
Juniper Pharmaceuticals resumed with a Buy at Roth Capital
Roth Capital analyst Yasmeen Rahimi resumed coverage of Juniper Pharmaceuticals with a Buy rating and $12 price target as she believes CRINONE is a money maker, the company's Intravaginal Ring Technology is one-of-a-kind, and given "three shots on goal" with JNP-0101, JNP-0201, and JNP-0301.
01/02/18
01/02/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Curo Group (CURO) was initiated with an Overweight at Stephens, an Outperform at Credit Suisse and William Blair, as well as a Buy at Jefferies. 2. Luther Burbank (LBC) was initiated with a Hold at Sandler O'Neill, a Neutral at DA Davidson and Piper Jaffray, as well as a Market Perform at Keefe Bruyette. 3. Denali Therapeutics (DNLI) was initiated with an Outperform at Evercore ISI, an Overweight at Morgan Stanley and JPMorgan, as well as a Neutral at Goldman Sachs. 4. Quanterix (QTRX) was initiated with an Outperform at Leerink and Cowen, an Overweight at JPMorgan, as well as a Buy at BTIG. 5. Juniper Pharmaceuticals (JNP) resumed with a Buy at Roth Capital. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
MKGAY Merck KGaA
$38.36

(0.00%)

AGN Allergan
$172.29

0.71 (0.41%)

12/08/17
RHCO
12/08/17
NO CHANGE
Target $53
RHCO
Buy
Revance price target raised to $53 from $32 at SunTrust
SunTrust analyst John Boris raised his price target on Revance (RVNC) to $53, saying the company's RT002's clinical data is "de-risked in glabellar lines", offering significant differentiation relative to Allegan's (AGN) Botox. Boris expects GL SAKURA data to be presented in February of 2018, modeling approval by the first half of 2020. The analyst also notes that the RT0002 Phase-2 plantar fasciitis data on track for December and the initiation of Phase 3 cervical dystonia trials for Q2 of next year, keeping his Buy rating on the stock.
12/19/17
FBCO
12/19/17
NO CHANGE
Target $214
FBCO
Outperform
Allergan price target lowered to $214 from $224 at Credit Suisse
Credit Suisse analyst Vamil Divan price target lowered to $214 from $224 following the company's disappointing performance during the latter part of 2017. The analyst notes that questions around base business and effect of LOEs have impacted stock, but expectations and valuation are now more reasonable. Divan reiterates an Outperform rating on the shares.
01/03/18
LEER
01/03/18
NO CHANGE
LEER
Outperform
Allergan restructuring as expected, risk to guidance low, says Leerink
Leerink analyst Seamus Fernandez says that Allergan's restructuring details announced this morning strongly suggest that the company can and will achieve its 2018 net income guidance. The analyst notes that his discussion with Allergan following today's press release confirmed that its 2018 guidance during the Q3 call did not include the impact of tax reform and that the one referenced in today's press release does not include it either. That said, since Restasis generics have not launched and appears unlikely prior to mid-2018, Fernandez believes the $15 floor guidance likely will be firmly intact with the $300-400M restructuring benefit announced today. The analyst reiterates an Outperform rating on the shares.
01/05/18
WELS
01/05/18
NO CHANGE
Target $245
WELS
Outperform
Allergan has built 'great barrier' around Botox, says Wells Fargo
Wells Fargo analyst David Maris conducted a survey of 25 plastic surgeons and dermatologists to gain insight on the changing neurotoxin landscape. The survey shows Allergan's (AGN) patient and physician loyalty programs and bundling discounts create a "great barrier" around Botox, Maris tells investors in a research note. It is unclear how significant a potential competitor Revance's (RVNC) RT002 could be to Allergan's largest product, the analyst adds. He believes that even with new innovative treatment options, Botox is expected to maintain its dominance in the neurotoxin market. Further, the analyst says that while RT002 showed statistically significant results at week 24 versus placebo, the endpoint doesn't seem not match the FDA's published guidance. Maris wonders if the data will be enough to get a six-month duration claim on the RT002 label, or if Revance is just hoping for an approval and then will point to the duration data. He keeps an Outperform rating on Allergan with a $245 price target.

TODAY'S FREE FLY STORIES

NBL

Noble Energy

$36.85

0.04 (0.11%)

, PES

Pioneer Energy

$5.95

0.3 (5.31%)

08:06
05/24/18
05/24
08:06
05/24/18
08:06
Conference/Events
UBS to hold a conference »

Global Oil & Gas…

NBL

Noble Energy

$36.85

0.04 (0.11%)

PES

Pioneer Energy

$5.95

0.3 (5.31%)

ECA

Encana

$13.34

0.02 (0.15%)

SOI

Solaris Oilfield

$16.46

0.26 (1.60%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    May

  • 02

    Aug

K

Kellogg

$62.31

0.79 (1.28%)

08:06
05/24/18
05/24
08:06
05/24/18
08:06
Recommendations
Kellogg analyst commentary  »

Kellogg offers attractive…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    May

  • 25

    May

AXDX

Accelerate Diagnostics

$21.05

-0.35 (-1.64%)

08:05
05/24/18
05/24
08:05
05/24/18
08:05
Initiation
Accelerate Diagnostics initiated  »

Accelerate Diagnostics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Jun

V

Visa

$131.90

1.185 (0.91%)

08:05
05/24/18
05/24
08:05
05/24/18
08:05
Hot Stocks
Visa announces strategic investment in YellowPepper »

Visa announced a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TTM

Tata Motors

$22.39

-0.52 (-2.27%)

08:04
05/24/18
05/24
08:04
05/24/18
08:04
Technical Analysis
Technical Take: Tata Motors down for second session to new 52-week low »

In pre-market trading the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JEF

Jefferies Financial Group

$23.47

-0.045 (-0.19%)

08:03
05/24/18
05/24
08:03
05/24/18
08:03
Hot Stocks
BattleFin names Jefferies as exclusive investment banking partner »

BattleFin announces an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

08:03
05/24/18
05/24
08:03
05/24/18
08:03
Conference/Events
Deutsche Bank to hold a conference »

Future Metals Corporate…

CEMI

Chembio Diagnostics

$8.70

-0.1 (-1.14%)

08:03
05/24/18
05/24
08:03
05/24/18
08:03
Hot Stocks
Chembio Diagnostics to commercialize disease tests in Brazil »

Chembio Diagnostics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

FHB

First Hawaiian

$28.94

0.07 (0.24%)

08:03
05/24/18
05/24
08:03
05/24/18
08:03
Conference/Events
First Hawaiian management to meet with Deutsche Bank »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    May

08:02
05/24/18
05/24
08:02
05/24/18
08:02
Conference/Events
Jefferies to hold a conference »

Automotive Aftermarket…

08:02
05/24/18
05/24
08:02
05/24/18
08:02
Conference/Events
Morgan Stanley to hold a symposium »

2nd Annual Small &…

MYO

Myomo

$3.28

-0.02 (-0.61%)

08:02
05/24/18
05/24
08:02
05/24/18
08:02
Hot Stocks
Myomo announces MyoPro availability in 16 new U.S. locations »

Myomo announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SKY

Skyline

$29.22

-0.56 (-1.88%)

08:01
05/24/18
05/24
08:01
05/24/18
08:01
Initiation
Skyline initiated  »

Skyline initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BX

Blackstone

$31.79

-0.08 (-0.25%)

08:01
05/24/18
05/24
08:01
05/24/18
08:01
Conference/Events
Detroit Economic Club to hold a luncheon »

Tony James, Executive…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    May

  • 30

    May

WHR

Whirlpool

$164.63

0.3 (0.18%)

08:01
05/24/18
05/24
08:01
05/24/18
08:01
Hot Stocks
Whirlpool announces preliminary results of modified Dutch auction tender offer »

Whirlpool Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jun

HFC

HollyFrontier

$73.67

0.75 (1.03%)

08:00
05/24/18
05/24
08:00
05/24/18
08:00
Recommendations
HollyFrontier analyst commentary  »

HollyFrontier price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JD

JD.com

$36.72

0.35 (0.96%)

08:00
05/24/18
05/24
08:00
05/24/18
08:00
Options
JD.com call buyer realizes 1% same-day gains »

Notable profits for the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UNP

Union Pacific

$144.26

1.36 (0.95%)

07:59
05/24/18
05/24
07:59
05/24/18
07:59
Initiation
Union Pacific initiated  »

Union Pacific resumed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Jun

NCR

NCR Corp.

$30.75

-0.4 (-1.28%)

07:58
05/24/18
05/24
07:58
05/24/18
07:58
Recommendations
NCR Corp. analyst commentary  »

NCR Corp. price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

07:55
05/24/18
05/24
07:55
05/24/18
07:55
Conference/Events
Federal Reserve Bank of Philadelphia President speaks at a conference »

Philadelphia Federal…

MCRB

Seres Therapeutics

$8.12

0.16 (2.01%)

07:55
05/24/18
05/24
07:55
05/24/18
07:55
Conference/Events
Seres Therapeutics to hold a research and development day »

Microbiome Research &…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    May

  • 02

    Jun

OKTA

Okta

$49.49

0.99 (2.04%)

07:52
05/24/18
05/24
07:52
05/24/18
07:52
Recommendations
Okta analyst commentary  »

Okta price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    May

  • 06

    Jun

  • 12

    Jun

INTU

Intuit

$196.15

5.74 (3.01%)

07:51
05/24/18
05/24
07:51
05/24/18
07:51
Recommendations
Intuit analyst commentary  »

Intuit price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Jun

CIT

CIT Group

$55.27

-0.06 (-0.11%)

07:51
05/24/18
05/24
07:51
05/24/18
07:51
Hot Stocks
CIT Group announces preliminary results of cash tender offer for common stock »

CIT Group announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EDU

New Oriental Education

$101.38

4.82 (4.99%)

07:50
05/24/18
05/24
07:50
05/24/18
07:50
Downgrade
New Oriental Education rating change  »

New Oriental Education…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.